Journal article
N. Temperton, D. Quenelle, K. Lawson, J. Zuckerman, E. Kern, P. Griffiths, V. Emery
Journal of medical virology, 2003
Journal of medical virology, 2003
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Temperton, N., Quenelle, D., Lawson, K., Zuckerman, J., Kern, E., Griffiths, P., & Emery, V. (2003). Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. Journal of Medical Virology.
Chicago/Turabian
Click to copy
Temperton, N., D. Quenelle, K. Lawson, J. Zuckerman, E. Kern, P. Griffiths, and V. Emery. “Enhancement of Humoral Immune Responses to a Human Cytomegalovirus DNA Vaccine: Adjuvant Effects of Aluminum Phosphate and CpG Oligodeoxynucleotides.” Journal of medical virology (2003).
MLA
Click to copy
Temperton, N., et al. “Enhancement of Humoral Immune Responses to a Human Cytomegalovirus DNA Vaccine: Adjuvant Effects of Aluminum Phosphate and CpG Oligodeoxynucleotides.” Journal of Medical Virology, 2003.
BibTeX Click to copy
@article{n2003a,
title = {Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides},
year = {2003},
journal = {Journal of medical virology},
author = {Temperton, N. and Quenelle, D. and Lawson, K. and Zuckerman, J. and Kern, E. and Griffiths, P. and Emery, V.}
}
Abstract
A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice. Intramuscular immunization of these mice with pRc/CMV2‐gB resulted in the generation of high levels of gpUL55‐specific antibody (geometric mean titer [GMT] 1:8900) and neutralizing antibody (GMT 1:74) after 2 booster doses given 5 and 10 weeks after primary inoculation. Emulsifying the construct with the aluminum phosphate gel adjuvant Adju‐Phos before immunization enhanced gpUL55‐specific antibody responses (GMT 1:17800, P = 0.04). Co‐immunization with CpG oligodeoxynucleotides was shown to enhance levels of neutralizing antibodies generated by immunization of mice with a pRc/CMV2‐gB/Adju‐Phos emulsion (P = 0.04). The results provide a rationale for evaluating combinations of other HCMV proteins for incorporation into a multi‐target DNA vaccine, and for the optimization of adjuvant usage, to elicit enhanced levels of neutralizing antibodies. J. Med. Virol. 70:86–90, 2003. © 2003 Wiley‐Liss, Inc.
